ImageBank | Home | Regular Bank
Shoot for 150-160 chars
Related Articles
Transplant and Nontransplant Salvage Therapy in Pediatric Relapsed or Refractory Hodgkin Lymphoma
This nonrandomized clinical trial in pediatric relapsed classic Hodgkin lymphoma tested fludeoxyglucose-18 positron emission tomography scans to identify patients in whom transplant-free salvage therapy would…
Subcutaneous Isatuximab Combo Hits Primary End Points in Phase 3 Trial
The phase 3 IRAKLIA trial of subcutaneous isatuximab met its co-primary end points in multiple myeloma.
3 QUESTIONS ON . . . ‘Spillover’ Savings for the Oncology… : Oncology Times
An abstract is unavailable.
Variant ZBTB16-RARA translocation: morphological changes predict cytogenetic variants of APL
Shoot for 150-160 chars
Program: Tuesday, February 25
tuesday, february 25 *-Short talk from proffered abstract CONTINENTAL BREAKFAST 7-8 a.m. Major Symposia 4-5 8-9:30 a.m. Major Symposium 4: Neoadjuvant Immunotherapy Session Chair: Christian…
Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC
Nivolumab plus ipilimumab has been approved in Europe for the frontline treatment of adult patients with MSI-H or dMMR metastatic colorectal cancer.
‘All for one’: City of Hope oncologist focuses on patients after evacuating fires
Ravi Salgia, MD, PhD, and his family were watching coverage of the Los Angeles County fires on their television around 6 p.m. Jan. 7 when…
Understanding the Mechanism and Sensitivity of BCL-2 Inhibitors
John Seymour, MBBS, FRACP, PhD, explains the mechanism of action of BCL-2 inhibitors like venetoclax.
Transplant-Free Approach in Relapsed Hodgkin Lymphoma in Children, Adolescents, and Young Adults
This nonrandomized clinical trial evaluates a risk-stratified, response-adapted, transplant-free approach for treatment of children, adolescents, and young adults with low-risk relapsed classic Hodgkin lymphoma with…
Neratinib Joins NCCN Guidelines for HER2-Mutated Cervical Cancer
The NCCN Guidelines have been updated to include neratinib for HER2-mutated recurrent/metastatic cervical cancer in the second line or later.